[ U.S. CDMRP – Melanoma Research Program Translational Research Award | Research Funding ]
Event details
| Date | 22.06.2020 |
| Category | Call for proposal |
Aim: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the Melanoma Research Program (MRP) Awards. The MRP Translational Research Award supports hypothesis-driven, translational, high-impact research. The TRA mechanism encourages applications with mature research projects that specifically focus on critical scientific or clinical melanoma issues, which, if successfully addressed, have the potential to make a major impact. Important factors under consideration will be continuity of research, clinical applicability, and leveraging of clinical samples from clinical trials and/or biorepositories.
The critical components of this award mechanism are:
To be considered for funding, applications must address at least one of the FY20 MRP Focus Areas, which are listed at the end of this announcement
Funding: max. $600’000 (single PI), $700’000 (collaborator option)
Duration: 3 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. PI applicants must be independent investigators at or above the level of Assistant Professor (or equivalent).
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a preproposal narrative, and a list of collaborators and key personnel as suggested on the platform. Full applications (by invitation) will be made via a Grants.gov workspace. Full application packages can be downloaded from Grants.gov at any time.
Pre-Application Deadline: 22-June-2020, 5:00 p.m. EST
Full Application Deadline: 24-September-2020, 11:59 p.m. EST
Grants.gov Funding Opportunity Number: W81XWH-20-MRP-TRA
Further information
FY20 Focus Areas
The critical components of this award mechanism are:
- Translation: The TRA is intended to support research that demonstrates the potential to have a major impact on an area of paramount importance in melanoma.
- Preliminary Data: The TRA is intended to support translational investigations that leapfrog the melanoma research field forward by utilizing previous research findings.
- Correlative Research: Studies funded by the TRA should leverage clinical samples from established biobanks, biorepositories, and/or ongoing or completed clinical trials.
- Collaborator Option: As a method to facilitate progress in addressing critical problems or questions through collaborative efforts, the FY20 MRP is offering a Collaborator Option for this award mechanism. The Collaborator Option is structured so that two investigators, each of whom will be designated as a PI, work synergistically on a single project.
To be considered for funding, applications must address at least one of the FY20 MRP Focus Areas, which are listed at the end of this announcement
Funding: max. $600’000 (single PI), $700’000 (collaborator option)
Duration: 3 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. PI applicants must be independent investigators at or above the level of Assistant Professor (or equivalent).
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a preproposal narrative, and a list of collaborators and key personnel as suggested on the platform. Full applications (by invitation) will be made via a Grants.gov workspace. Full application packages can be downloaded from Grants.gov at any time.
Pre-Application Deadline: 22-June-2020, 5:00 p.m. EST
Full Application Deadline: 24-September-2020, 11:59 p.m. EST
Grants.gov Funding Opportunity Number: W81XWH-20-MRP-TRA
Further information
- To see the program announcement, navigate to the search page on Grants.gov and search for the Opportunity Number W81XWH-20-MRP-TRA
- For questions about the eBRAP or Grants.gov platforms, contact the Research Office.
FY20 Focus Areas
- Prevention of melanoma initiation factors (e.g., UV radiation)
- Prevention of melanomagenesis and precursor lesions (e.g., novel genetic and epigenetic drivers, oncogene induced senescence)
- Understanding the tumor microenvironment
- Bioengineering (e.g., computational, imaging) approaches to address diagnostics, high risk markers, dormancy, and metastasis
- Therapeutic Prevention (e.g., interruption of disease progression, recurrence)
- Minimal Residual Disease (e.g., chemoprevention, micro-metastasis)
Practical information
- General public
- Free